EP Patent

EP4008318A1 — A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2022-06-08 · 4y expired

What this patent protects

The present invention relates to a process for the preparation of a film coated tablet formulation comprising amorphous dapagliflozin and metformin hydrochloride. The process is wet-granulation which is simple, rapid, cost effective, time-saving and industrially convenient proces…

USPTO Abstract

The present invention relates to a process for the preparation of a film coated tablet formulation comprising amorphous dapagliflozin and metformin hydrochloride. The process is wet-granulation which is simple, rapid, cost effective, time-saving and industrially convenient process and is created to eliminate the disadvantages of both active ingredients.

Drugs covered by this patent

Patent Metadata

Patent number
EP4008318A1
Jurisdiction
EP
Classification
—
Expires
2022-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.